Analysis on survival and prognostic factors for cancer patients with malignancy-associated hypercalcemia

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6715-6719

  Zhang, Su Jie ^a   Hu, Yi ^a   Cao, Jing ^a   Qian, Hai Li ^b   Jiao, Shun Chang ^a   Liu, Zhe Feng ^a   Tao, Hai Tao ^a   Han, Lu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CANCER HOSPITAL   (China)

Author keywords

Cancer; CNS symptoms; Gender; Hypercalcemia; Prognostic factor

Indexed keywords

EID: 84892447079     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6715     Document Type: Article

References (30)

1. Body JJ, Facon T, Coleman RE, et al (2006). A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res, 12, 1221-8.
2. Body JJ, Lipton A, Gralow J, et al (2010). Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure. J Bone Miner Res, 25, 440-6.
3. Buchner-Daley L, Brady-West D, McGrowder D (2012). Clinical and biochemical profile of monoclonal gammopathies in caribbean patients in a resource-limited setting. Asian Pac J Cancer Prev, 13, 6501-4.
4. Clines GA (2011). Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes, 18, 339-46.
5. Croucher PI, Shipman CM, Lippitt J, et al (2001). Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood, 98, 3534-40.
6. Ding H, Yang L, Du W, et al (2013). Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 14, 3337-43.
7. Foussas SG, Zairis MN, Makrygiannis SS, et al (2007). The significance of circulating levels of both cardiac troponin I and high-sensitivity C reactive protein for the prediction of intravenous thrombolysis outcome in patients with STsegment elevation myocardial infarction. Heart, 93, 952-6.
8. Grill V, Martin TJ (2000). Hypercalcemia of malignancy. Endocr Metab Disord, 1, 253-63.
9. Hassan BA, YusoffZB, Hassali MA, et al (2012). Impact of chemotherapy on hypercalcemia in breast and lung cancer patients. Asian Pac J Cancer Prev, 13, 4373-8.
10. Lazaretti-Castro M, Kayath M, Jamnik S, et al (1993). Prevalence of hypercalcemia in patients with lung cancer. Rev Assoc Med Bras, 39, 83-7.
11. Le Tinier F, Vanhuyse M, Penel N, et al (2011). Cancerassociated hypercalcaemia in squamous-cell malignancies: a survival and prognostic factor analysis. Int J Oral Maxillofac Surg, 40, 938-42.
12. Li B, Ling Chau, JF, Wang X, et al (2011). Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. J Cell Biochem, 112, 1229-42.
13. Lorch G, Viatchenko-Karpinski S, Ho HT, et al (2011). The calcium-sensing receptor is necessary for the rapid development of hypercalcemia in human lung squamous cell carcinoma. Neoplasia, 13, 428-38.
14. Lumachi F, Brunello A, Roma A, et al (2009). Cancer-induced hypercalcemia. Anticancer Res, 29, 1551-5.
15. Morony S, Warmington K, Adamu S, et al (2005). The inhibition of RANKL causes a greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia in malignancy. Endocrinology, 146, 3235-43.
16. Neville-Webbe HL, Coleman RE, et al (2010). Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer, 46, 1211-22.
17. Neville-Webbe, HL, Coleman, RE (2010). Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer, 46, 1211-22.
18. Penel N, Dewas S, Doutrelant P, et al (2008). Cancer-associated hypercalcemia treated by intravenous diphosphonates: a survival and prognostic factor analysis. Support Care Cancer, 16, 387-92.
19. Penel N, Dewas S, Doutrelant P, et al (2008). Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis. Support Care Cancer, 16, 387-92.
20. Sato K, Onuma E, Yocum RC, et al (2003). Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody. Semin Oncol, 30, 167-73.
21. Schwartz AG, Prysak GM, Murphy V, et al (2005). Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res, 11, 7280-7.
22. Shi Y, Dai GH, Jiao SC (2008). Clinical characteristics and prognostic factors of 22 malignant hypercalcemia cases. Chin Clin Oncol, 13, 12.
23. Sookprasert A, Pugkhem A, Khuntikeo N, et al (2012). Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients - a pilot study. Asian Pac J Cancer Prev, 13, 161-7.
24. Stewart, AF (2005). Clinical Practice. Hypercalcemia associated with cancer. N Engl J Med, 352, 373-9.
25. Stopeck A, de Boer R, Fujiwara Y, et al (2009). A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases. 32nd San Antonio Breast Cancer Symposium, abs. 22.
26. Tanaka S, Nakamura K, Takahasi N, et al (2005). Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev, 208, 30-49.
27. Teo M, Dhadda A, Gunn J (2008). Paraneoplastic hypercalcaemia in squamous cell carcinoma of the anus: first reported case. Clin Oncol (RCollRadiol), 20, 718.
28. Truong NU, deB Edwardes MD, Papavasiliou V, et al (2003). Parathyroid hormone-related peptide and survival with cancer and hypercalcemia. Am J Med, 115, 115-21.
29. Vallet S, Smith MR, Raje N (2010). Novel bonetargeted strategies in oncology. Clin Cancer Res, 16, 4084-93.
30. Xie CY, Hu YD, Wang LL, et al (2006). Clinical analysis of 13 patients diagnosed lung cancer with hypercalcemia. J Third Milit Med Univ, 28, 2.